Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultrarare disease therapies, has announced the grant of 7,750 restricted stock units to eight newly hired non-executive officers. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan on January 16, 2025. The grants serve as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units feature a four-year vesting schedule, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment.
Ultragenyx Pharmaceutical (NASDAQ: RARE), un'azienda biofarmaceutica specializzata nelle terapie per malattie rare e ultrarare, ha annunciato l'assegnazione di 7.750 unità azionarie vincolate a otto nuovi dirigenti non esecutivi. Il comitato di compensazione ha approvato questi riconoscimenti nell'ambito del Piano di Induzione all'Occupazione Ultragenyx il 16 gennaio 2025. Le assegnazioni servono come incentivo all'occupazione in conformità con la Regola di Quotazione di Nasdaq 5635(c)(4). Le unità azionarie vincolate presentano un programma di maturazione di quattro anni, con il 25% delle azioni che matura annualmente nell'anniversario della data di assegnazione, a condizione di occupazione continuativa.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una compañía biofarmacéutica especializada en terapias para enfermedades raras y ultrararas, ha anunciado la concesión de 7,750 unidades de acciones restringidas a ocho nuevos funcionarios no ejecutivos. El comité de compensación aprobó estos premios bajo el Plan de Inducción al Empleo de Ultragenyx el 16 de enero de 2025. Las concesiones sirven como incentivos de empleo de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4). Las unidades de acciones restringidas cuentan con un programa de adquisición de cuatro años, con el 25% de las acciones adquiriéndose anualmente en el aniversario de la fecha de concesión, sujeto a empleo continuado.
Ultragenyx Pharmaceutical (NASDAQ: RARE), 희귀 및 초희귀 질환 치료에 전문화된 생명공학 회사가 새로 고용된 비임원 직원 여덟 명에게 7,750개의 제한된 주식 단위를 부여한다고 발표했습니다. 보상 위원회는 2025년 1월 16일 Ultragenyx 고용 유인 계획에 따라 이러한 보상을 승인했습니다. 이 보상은 Nasdaq 상장 규정 5635(c)(4)에 따라 고용 유인으로 제공됩니다. 제한된 주식 단위는 4년의 취득 일정을 가지고 있으며, 주식의 25%는 부여일 기념일에 매년 취득되며, 지속적인 고용이 조건입니다.
Ultragenyx Pharmaceutical (NASDAQ: RARE), une société biopharmaceutique spécialisée dans les thérapies pour les maladies rares et ultrarares, a annoncé l'octroi de 7 750 unités d'actions restreintes à huit nouveaux directeurs non exécutifs. Le comité de rémunération a approuvé ces récompenses dans le cadre du Plan d'Induction à l'Emploi Ultragenyx le 16 janvier 2025. Les allocations servent d'incitatifs à l'emploi conformément à la Règle de Cotation Nasdaq 5635(c)(4). Les unités d'actions restreintes disposent d'un calendrier d'acquisition de quatre ans, avec 25 % des actions acquis chaque année à l'anniversaire de la date d'octroi, sous réserve d'un emploi continu.
Ultragenyx Pharmaceutical (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene und ultrarare Krankheiten spezialisiert hat, hat die Vergabe von 7.750 eingeschränkten Aktieneinheiten an acht neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte diese Auszeichnungen im Rahmen des Ultragenyx Employment Inducement Plans am 16. Januar 2025. Die Zuschüsse dienen als Anreiz für die Beschäftigung in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4). Die eingeschränkten Aktieneinheiten haben einen vierjährigen Vesting-Zeitplan, bei dem 25 % der Aktien jährlich am Jahrestag des Zuteilungsdatums fällig werden, vorausgesetzt, die Beschäftigung bleibt bestehen.
- Stock-based compensation aligns new employee interests with shareholder value
- 7,750 new restricted stock units will create minor shareholder dilution
NOVATO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 7,750 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of January 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant in January 2025?
What is the vesting schedule for Ultragenyx's (RARE) January 2025 restricted stock units?
Under which plan were Ultragenyx's (RARE) January 2025 stock grants issued?
How many new non-executive officers received RARE stock grants in January 2025?
